Copyright
©The Author(s) 2020.
World J Gastroenterol. Mar 14, 2020; 26(10): 1042-1055
Published online Mar 14, 2020. doi: 10.3748/wjg.v26.i10.1042
Published online Mar 14, 2020. doi: 10.3748/wjg.v26.i10.1042
Table 1 Patient demographics and clinical characteristics, n (%)
Original data | Matched data | |||||
Characteristic | PA-TACE | Surgery alone | P value | PA-TACE | Surgery alone | P value |
Age (yr) | < 0.001 | 0.889 | ||||
< 65 | 196 (73.0) | 281 (66.0) | 158 (83.6) | 159 (84.1) | ||
≥ 65 | 31 (13.7) | 145 (34.0) | 31 (16.4) | 30 (15.9) | ||
Gender | 0.245 | 0.866 | ||||
Male | 197 (86.8) | 355 (83.3) | 170 (89.9) | 169 (89.4) | ||
Female | 30 (13.2) | 71 (16.7) | 19 (10.1) | 20 (10.6) | ||
BMI | 0.074 | 0.905 | ||||
< 23 | 97 (42.7) | 188 (44.1) | 84 (44.4) | 81 (42.9) | ||
23-25 | 76 (33.5) | 110 (25.8) | 57 (30.2) | 61 (32.3) | ||
≥ 25 | 54 (23.8) | 128 (30.0) | 48 (25.4) | 47 (24.9) | ||
BCLC stage | 0.509 | 0.614 | ||||
0 | 43 (18.9) | 90 (21.1) | 38 (20.1) | 42 (22.2) | ||
A | 184 (81.1) | 336 (78.9) | 151 (79.9) | 147 (77.8) | ||
HBV | < 0.001 | 0.362 | ||||
Negative | 25 (11.0) | 101 (23.7) | 22 (11.6) | 28 (14.8) | ||
Positive | 202 (89.0) | 325 (76.3) | 167 (88.4) | 161 (85.2) | ||
HCV | 0.282 | 0.351 | ||||
Negative | 218 (96.0) | 402 (94.4) | 183 (96.8) | 182 (96.3) | ||
Positive | 3 (1.4) | 3 (0.7) | 0 (0) | 2 (1.1) | ||
Unknown | 6 (2.6) | 21 (4.9) | 6 (3.2) | 5 (2.6) | ||
Cirrhosis | 0.067 | 0.678 | ||||
No | 114 (50.2) | 182 (42.7) | 83 (43.9) | 79 (41.8) | ||
Yes | 113 (49.8) | 224 (57.3) | 106 (56.1) | 110 (58.2) | ||
Family history | 0.605 | 0.876 | ||||
No | 200 (88.1) | 381 (89.4) | 166 (87.8) | 165 (87.3) | ||
Yes | 27 (11.9) | 45 (10.6) | 23 (12.2) | 24 (12.7) | ||
MVI | 0.006 | 0.884 | ||||
No | 187 (82.4) | 383 (89.9) | 161 (85.2) | 162 (85.7) | ||
Yes | 40 (17.6) | 43 (10.1) | 28 (14.8) | 27 (14.3) | ||
AFP (ng/mL) | < 0.001 | 1.000 | ||||
≤ 200 | 96 (42.3) | 252 (59.2) | 96 (50.8) | 96 (50.8) | ||
> 200 | 131 (57.7) | 174 (40.8) | 93 (49.2) | 93 (49.2) | ||
ALBI grade | 0.001 | 0.678 | ||||
1 | 129 (56.8) | 223 (52.3) | 104 (55.0) | 108 (57.1) | ||
2 | 92 (40.5) | 203 (47.7) | 85 (45.0) | 81 (42.9) | ||
3 | 6 (2.6) | 0 (0) | - | - | ||
NLR | 0.986 | 0.918 | ||||
≤ Median | 116 (51.1) | 218 (51.2) | 86 (45.5) | 85 (45.0) | ||
> Median | 111 (48.9) | 208 (48.8) | 103 (54.5) | 104 (55.0) | ||
Ferritin (ng/mL) | 0.196 | 0.914 | ||||
≤ 400 | 147 (64.8) | 297 (69.7) | 125 (66.1) | 124 (65.6) | ||
> 400 | 80 (35.2) | 129 (30.3) | 64 (33.9) | 65 (34.4) | ||
FHR | 0.095 | 0.918 | ||||
≤ Median | 114 (50.2) | 243 (57.0) | 98 (51.9) | 97 (51.3) | ||
> Median | 113 (49.8) | 183 (43.0) | 91 (48.1) | 92 (48.7) | ||
CRP (mg/L) | 0.089 | 0.341 | ||||
≤ 5 | 176 (77.5) | 304 (71.4) | 138 (73.0) | 146 (77.2) | ||
> 5 | 51 (22.5) | 122 (28.6) | 51 (27.0) | 43 (22.8) | ||
Times | - | - | ||||
1 | 166 (73.1) | - | 136 (71.9) | - | ||
2 | 55 (24.2) | - | 47 (24.9) | - | ||
> 3 | 6 (2.7) | - | 6 (3.2) | - |
Table 2 Prognostic factors for overall survival based on univariate analysis of the matched data
PA-TACE | Surgery alone | |||||
Characteristic | Hazard ratio | 95%CI | P value | Hazard ratio | 95%CI | P value |
Age (yr) | 0.043 | 0.166 | ||||
< 65 | Reference | Reference | ||||
≥ 65 | 0.300 | 0.093-0.963 | 0.043 | 1.490 | 0.848-2.619 | 0.166 |
Gender | 0.578 | 0.001 | ||||
Male | Reference | Reference | ||||
Female | 0.785 | 0.334-1.844 | 0.578 | 0.382 | 0.217-0674 | 0.001 |
BMI | 0.187 | 0.121 | ||||
< 23 | Reference | Reference | ||||
23-25 | 0.497 | 0.233-1.060 | 0.070 | 0.859 | 0.525-1.407 | 0.546 |
≥ 25 | 0.912 | 0.476-1.747 | 0.781 | 0.517 | 0.275-0.971 | 0.040 |
BCLC stage | 0.015 | 0.045 | ||||
0 | Reference | Reference | ||||
A | 4.287 | 1.333-13.785 | 0.015 | 1.839 | 1.014-3.403 | 0.045 |
HBV | 0.693 | 0.038 | ||||
Negative | Reference | Reference | ||||
Positive | 1.205 | 0.478-3.038 | 0.693 | 2.414 | 1.049-5.553 | 0.038 |
HCV | 0.367 | 0.645 | ||||
Negative | Reference | Reference | ||||
Positive | - | - | 0 | 0.000-NA | 0.963 | |
Unknown | 0.047 | 0-36.104 | 0.367 | 0.390 | 0.054-2.804 | 0.350 |
Cirrhosis | 0.166 | 0.129 | ||||
No | Reference | Reference | ||||
Yes | 1.516 | 0.841-2.730 | 0.166 | 1.440 | 0.899-2.307 | 0.129 |
Family history | 0.936 | 0.543 | ||||
No | Reference | Reference | ||||
Yes | 0.966 | 0.411-2.269 | 0.936 | 0.806 | 0.402-1.615 | 0.543 |
MVI | 0.005 | 0.439 | ||||
No | Reference | Reference | ||||
Yes | 2.557 | 1.332-4.910 | 0.005 | 1.275 | 0.689-2.359 | 0.439 |
AFP (ng/mL) | 0.429 | 0.416 | ||||
≤ 200 | Reference | Reference | ||||
> 200 | 1.255 | 0.715-2.203 | 0.429 | 1.203 | 0.771-1.878 | 0.416 |
ALBI grade | 0.085 | < 0.001 | ||||
1 | Reference | Reference | ||||
2 | 1.637 | 0.934-2.871 | 0.085 | 2.303 | 1.466-3.620 | < 0.001 |
3 | - | - | - | - | - | - |
NLR | 0.962 | 0.578 | ||||
≤ Median | Reference | Reference | ||||
> Median | 0.986 | 0.563-1729 | 0.962 | 0.881 | 0.564-1.376 | 0.578 |
Ferritin (ng/mL) | 0.056 | 0.323 | ||||
≤ 400 | Reference | Reference | ||||
> 400 | 1.731 | 0.986-3.040 | 0.056 | 1.447 | 0.695-3.015 | 0.323 |
FHR | 0.001 | < 0.001 | ||||
≤ Median | Reference | Reference | ||||
> Median | 2.830 | 1.541-5.198 | 0.001 | 4.084 | 2.452-6.802 | < 0.001 |
CRP (mg/L) | 0.670 | 0.875 | ||||
≤ 5 | Reference | Reference | ||||
> 5 | 0.864 | 0.441-1.691 | 0.670 | 1.043 | 0.616-1.767 | 0.875 |
Times | 0.193 | - | ||||
1 | Reference | - | - | |||
2 | 0.661 | 0.319-1.370 | 0.266 | - | - | |
3 | 2.171 | 0.668-7.059 | 0.197 | - | - |
Table 3 Identification of prognostic factors for overall survival based on multivariate analysis of the matched data
PA-TACE | Surgery Alone | |||||
Characteristic | Hazard ratio | 95%CI | P value | Hazard ratio | 95%CI | P value |
Age (yr) | 0.023 | - | ||||
< 65 | Reference | - | - | - | ||
≥ 65 | 0.257 | 0.080-0.826 | 0.023 | - | - | - |
Gender | - | 0.027 | ||||
Male | - | - | - | Reference | ||
Female | - | - | - | 0.523 | 0.294-0.930 | 0.027 |
BCLC stage | 0.021 | 0.036 | ||||
0 | Reference | Reference | ||||
A | 3.972 | 1.23-12.825 | 0.021 | 1.963 | 1.044-3.689 | 0.036 |
HBV | - | 0.034 | ||||
Negative | - | - | - | Reference | ||
Positive | - | - | - | 1.982 | 1.013-4.736 | 0.034 |
MVI | 0.002 | - | ||||
No | Reference | - | - | - | ||
Yes | 2.850 | 1.475-5.506 | 0.002 | - | - | - |
ALBI grade | - | 0.027 | ||||
1 | - | - | - | Reference | ||
2 | - | - | - | 1.732 | 1.064-2.821 | 0.027 |
3 | - | - | - | - | - | - |
FHR | < 0.001 | < 0.001 | ||||
≤ Median | Reference | Reference | ||||
> Median | 3.338 | 1.810-6.157 | < 0.001 | 1.963 | 1.044-3.689 | < 0.001 |
Table 4 Predictive factors for treatment response: Postoperative adjuvant transcatheter arterial chemoembolization vs surgery alone
Events, n (%) | 5-yr survival rate, % | ||||||
Characteristic | PA-TACE | Surgery alone | PA-TACE | Surgery alone | HR(P/S) | 95%CI | P value for interaction |
Age (yr) | 0.059 | ||||||
< 65 | 46 (29.3) | 63 (39.6) | 70.9 | 60.4 | 0.653 | 0.347-0.956 | |
≥ 65 | 3 (9.7) | 15 (50.0) | 90.3 | 50.0 | 0.164 | 0.040-0.584 | |
Gender | 0.131 | ||||||
Male | 43 (25.3) | 63 (37.3) | 74.7 | 62.7 | 0.598 | 0.406-0.882 | |
Female | 4 (21.1) | 7 (35.0) | 78.9 | 65.0 | 0.270 | 0.104-0.703 | |
BMI | 0.261 | ||||||
< 23 | 26 (31.0) | 38 (46.9) | 69.0 | 53.1 | 0.530 | 0.321-0.873 | |
23-25 | 9 (15.8) | 27 (44.3) | 84.2 | 55.7 | 0.315 | 0.148-0.671 | |
≥ 25 | 14 (29.2) | 13 (27.7) | 70.8 | 72.3 | 0.973 | 0.457-2.070 | |
BCLC stage | 0.236 | ||||||
0 | 3 (7.9) | 12 (28.6) | 92.1 | 71.4 | 0.256 | 0.072-0.909 | |
A | 46 (30.5) | 66 (44.9) | 69.5 | 55.1 | 0.570 | 0.391-0.830 | |
HBV | 0.274 | ||||||
Negative | 5 (22.7) | 6 (21.4) | 77.3 | 78.6 | 0.988 | 0.302-3.247 | |
Positive | 44 (26.3) | 72 (44.7) | 73.7 | 55.3 | 0.493 | 0.339-0.717 | |
HCV | 0.527 | ||||||
Negative | 49 (26.8) | 77 (42.3) | 73.2 | 57.7 | 0.560 | 0.376-0.770 | |
Positive | 0 (0) | 0 (0) | 100 | 100 | - | - | |
Unknown | 0 (0) | 1 (20.0) | 100 | 80.0 | 0.013 | 0.000-1357 | |
Cirrhosis | 0.943 | ||||||
No | 17 (20.5) | 26 (32.9) | 79.5 | 67.1 | 0.550 | 0.298-1.013 | |
Yes | 32 (30.2) | 52 (47.3) | 69.8 | 52.7 | 0.535 | 0.345-0.832 | |
Family History | 0.793 | ||||||
No | 43 (25.9) | 69 (41.8) | 74.1 | 58.2 | 0.528 | 0.360-0.772 | |
Yes | 6 (26.1) | 9 (37.5) | 73.9 | 62.5 | 0.612 | 0.218-1.721 | |
MVI | 0.048 | ||||||
No | 37 (23.0) | 66 (40.7) | 77.0 | 59.3 | 0.469 | 0.313-0.701 | |
Yes | 12 (42.9) | 12 (44.4) | 57.1 | 55.6 | 0.911 | 0.605-1.708 | |
AFP | 0.984 | ||||||
≤ 200 ng/mL | 22 (22.9) | 36 (37.5) | 77.1 | 62.5 | 0.529 | 0.311-0.898 | |
> 200 ng/mL | 27 (29.0) | 42 (45.2) | 71.0 | 54.8 | 0.533 | 0.328-0.865 | |
ALBI grade | 0.333 | ||||||
1 | 23 (22.1) | 32 (29.6) | 77.9 | 70.4 | 0.647 | 0.378-1.105 | |
2 | 26 (30.6) | 46 (56.8) | 69.4 | 43.2 | 0.453 | 0.280-0.734 | |
3 | - | - | - | - | - | - | |
NLR | 0.791 | ||||||
≤ Median | 23 (26.7) | 36 (42.4) | 73.3 | 57.6 | 0.510 | 0.302-0.860 | |
> Median | 26 (25.2) | 42 (40.3) | 74.8 | 59.6 | 0.562 | 0.344-0.917 | |
Ferritin | 0.289 | ||||||
≤ 400 ng/mL | 27 (21.6) | 33 (26.6) | 78.4 | 73.4 | 0.691 | 0.354-1.349 | |
> 400 ng/mL | 22 (34.4) | 45 (69.2) | 65.6 | 30.8 | 0.450 | 0.294-0.688 | |
FHR | 0.038 | ||||||
≤ Median | 15 (15.3) | 20 (20.6) | 84.7 | 79.4 | 0.748 | 0.450-1.244 | |
> Median | 34 (37.4) | 58 (63.0) | 62.6 | 37.0 | 0.348 | 0.209-0.582 | |
CRP | 0.853 | ||||||
≤ 5 mg/L | 38 (27.5) | 60 (41.1) | 72.5 | 58.9 | 0.556 | 0.370-0.835 | |
> 5 mg/L | 11 (21.6) | 18 (41.9) | 78.4 | 58.1 | 0.513 | 0.242-1.088 |
- Citation: Chen MY, Juengpanich S, Hu JH, Topatana W, Cao JS, Tong CH, Lin J, Cai XJ. Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma. World J Gastroenterol 2020; 26(10): 1042-1055
- URL: https://www.wjgnet.com/1007-9327/full/v26/i10/1042.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i10.1042